TrialBreast cancer research and treatment2013

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Eleni Andreopoulou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.